ArticleWorld journal of gastroenterology2014
Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Inflammatory factors collaboratively linkFrontiers in immunology · 2025Review
- Network pharmacology study andWorld journal of gastrointestinal oncology · 2024Article
- Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.Current issues in molecular biology · 2024Review
- Review
- Loss of RNA binding protein HuD facilitates the production of the senescence-associated secretory phenotype.Cell death & disease · 2022Article
- Application progress of liquid biopsy in gastric cancer.Frontiers in oncology · 2022Review
- Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism.Frontiers in genetics · 2022Review
- Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.Cell proliferation · 2021Review
- Uncovering the Mechanisms and Molecular Targets of Weibing Formula 1 against Gastritis: Coupling Network Pharmacology with GEO Database.BioMed research international · 2021Article
- Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?International journal of molecular sciences · 2020Review
- The Role of Chemokines in the Development of Gastric Cancer - Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2020Review
- Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor-A Literature Review.International journal of molecular sciences · 2020Review
- Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.BMC cancer · 2019Article
- Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.Cancer science · 2019Review
- Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy.Current topics in microbiology and immunology · 2019Review
- Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis.BMC complementary and alternative medicine · 2018Article
- Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies.Targeted oncology · 2018Review
- Association of mast cell infiltration with gastric cancer progression.Oncology letters · 2018Article
- Tumor Acidosis and Hypoxia Differently Modulate the Inflammatory Program: Measurements In Vitro and In Vivo.Neoplasia (New York, N.Y.) · 2017Article
- Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.Cancer immunology, immunotherapy : CII · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the expression and prognostic value of CCL2 in gastric cancer, as well as its relationship with tumor hypoxia.
methodsTumor tissues from 68 gastric cancer patients (GC) were analyzed, and the expression of CCL2 and hypoxia-inducible factor 1 alpha (HIF-1α) in tumor tissues was detected by immunohistochemistry. Statistical evaluations that were used included univariate log-rank tests of Kaplan-Meier curves and multivariate Cox regression model analysis.
resultsCCL2 was highly expressed in 66.2% (45/68) of gastric cancer specimens. The distribution of CCL2 expression in tumor tissue was consistent with that of HIF-1α. Patients with high CCL2 expression in GC had a lower overall survival rate [50.6 mo (95%CI: 44.44-56.93) vs 64.6 mo (95%CI: 60.27-68.94), P = 0.013].
conclusionCCL2 expression correlates closely with HIF-1α expression in gastric cancer. CCL2 may be an independent prognostic marker for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.